Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES        
Net income (loss) $ (4,232) $ (6,415)    
Income from discontinuing operations (74) (561)    
Loss from continuing operations (4,306) (6,976)    
Adjustments to reconcile net loss to net cash used in operating activities, continuing operations:        
Depreciation 130 53    
Amortization 332 328    
Stock-based compensation 152 226    
Impairment of goodwill 0 2,873    
Change in fair value of warrant liability, acquisition note payable and other derivatives (137) (331)    
Amortization of operating lease right-of-use assets 154 123    
Change in fair value of siParadigm Earn-Out 66 982    
Amortization of discount on debt and debt issuance costs 71 470    
Loss on extinguishment of debt 120 256    
Interest added to Convertible Note 0 268    
Changes in:        
Accounts receivable (72) (36)    
Other current assets (203) (422)    
Other non-current assets (3) (2)    
Accounts payable, accrued expenses and deferred revenue 400 1,516    
Due to Interpace Biosciences, Inc. 421 0    
Obligations under operating leases (183) (156)    
Net cash used in operating activities, continuing operations (3,058) (828)    
Net cash used in operating activities, discontinuing operations (514) (5,309)    
Net cash used in operating activities (3,572) (6,137)    
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of fixed assets (39) (21)    
Distribution from Joint Venture 36 0    
Receipts from Excess Consideration Note 888 0    
Net cash provided by (used in) investing activities, continuing operations 885 (21)    
Net cash provided by investing activities, discontinuing operations 78 3,044    
Net cash provided by investing activities 963 3,023    
CASH FLOWS FROM FINANCING ACTIVITIES        
Principal payments on obligations under finance leases (66) (36)    
Proceeds from offerings of common stock, net of certain offering costs 0 5,412    
Payments on Advance from NovellusDx, Ltd. (350) 0    
Net cash provided by (used in) financing activities, continuing operations (416) 5,376    
Net cash used in financing activities, discontinuing operations 0 (115)    
Net cash provided by (used in) financing activities (416) 5,261    
Effect of foreign exchange rates on cash and cash equivalents and restricted cash (72) (161)    
Net increase (decrease) in cash and cash equivalents and restricted cash (3,097) 1,986    
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH        
Beginning 4,230 511    
Ending 1,133 2,497    
RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:        
Cash and cash equivalents     $ 1,133 $ 2,147
Restricted cash     0 350
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH 1,133 2,497 1,133 2,497
SUPPLEMENTAL CASH FLOW DISCLOSURE        
Cash paid for interest 11 1,185    
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES        
Common stock issued in VentureEast settlement 12 0    
Fair value of common stock exchanged to settle Note Payable 1,578 0    
Right of use assets obtained through operating leases 27 0    
Fixed assets obtained through finance leases 17 145    
Conversion of debt and accrued interest into common stock 0 350    
Increase in fair value of embedded conversion option 0 547    
Exchanges of principal on Convertible Note for common stock 0 612    
Disposal of Business        
Accounts receivable     0  
Operating lease right-of-use assets 0 436    
Note receivable from IDXG     0  
Advance, net     0  
Clinical Business        
Disposal of Business        
Goodwill     0 1,188
Accounts payable and accrued expenses     0 (287)
Gain on disposal of business 0 1,222    
Earn-Out from siParadigm     0 (2,269)
Advance, net     0 974
Net cash received in disposal 0 828    
BioPharma Disposal        
Disposal of Business        
Accounts receivable     0 4,145
Other current assets     0 1,142
Fixed assets     0 2,998
Operating lease right-of-use assets 0 1,969    
Patents and other intangible assets     0 42
Goodwill     0 10,106
Accounts payable and accrued expenses     0 (6,351)
Obligations under operating leases     0 (2,110)
Obligations under finance leases     0 (451)
Deferred revenue     0 (1,046)
Line of credit     0 (2,665)
Term note     0 (6,000)
Gain on disposal of business 0 7,274    
Note receivable from IDXG     $ 0 $ (6,795)
Net cash received in disposal $ 0 $ 2,258